Zhang Q, Wang F Z, Ma C, An Z J, Yin Z D
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Dec 6;55(12):1371-1376. doi: 10.3760/cma.j.cn112150-20211015-00951.
The Delta variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a new global wave of the Coronavirus Disease 2019 (COVID-19) pandemic. COVID-19 vaccines currently available in China show high effectiveness against severe illness and death. However, transmission of the virus is not fully stopped by vaccination alone, therefore, integrated vaccination and non-pharmacological interventions is necessary to prevent and control the epidemic in the near future. Further expanded vaccine coverage of primary doses as well as booster shots in China's domestic population are needed to reduce severe illness and death. In order to provide evidence necessary for adjusting and optimizing immunization strategies and pandemic control measures, it is essential to conduct research on vaccine effectiveness against emerging variants, persistence of vaccine-induced protection, surveillance of adverse event following immunization with large-scale vaccine use, and modelling studies on strategic combinations of vaccination and non-pharmacological interventions.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的德尔塔变异株引发了新一轮全球2019冠状病毒病（COVID-19）大流行。中国目前可用的COVID-19疫苗对重症和死亡显示出高有效性。然而，仅靠接种疫苗并不能完全阻止病毒传播，因此，在不久的将来，综合接种疫苗和非药物干预措施对于预防和控制疫情是必要的。需要进一步扩大中国国内人群的基础剂量疫苗接种以及加强针接种，以减少重症和死亡。为了提供调整和优化免疫策略及疫情防控措施所需的证据，开展针对新出现变异株的疫苗有效性研究、疫苗诱导保护的持久性研究、大规模使用疫苗后免疫接种不良反应监测以及疫苗接种与非药物干预措施策略组合的建模研究至关重要。
